HC Wainwright Issues Pessimistic Forecast for SRTS Earnings

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Investment analysts at HC Wainwright cut their Q2 2025 earnings per share estimates for shares of Sensus Healthcare in a research note issued on Monday, February 10th. HC Wainwright analyst Y. Chen now expects that the company will earn $0.07 per share for the quarter, down from their prior estimate of $0.10. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.71 per share. HC Wainwright also issued estimates for Sensus Healthcare’s FY2025 earnings at $0.44 EPS.

Several other analysts also recently weighed in on the company. Lake Street Capital initiated coverage on Sensus Healthcare in a research report on Friday, January 31st. They set a “buy” rating and a $18.00 price objective for the company. Maxim Group boosted their target price on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, November 15th.

Sensus Healthcare Stock Performance

Shares of SRTS stock opened at $5.93 on Wednesday. Sensus Healthcare has a fifty-two week low of $2.91 and a fifty-two week high of $9.33. The stock’s fifty day moving average price is $7.33 and its two-hundred day moving average price is $6.89. The company has a market cap of $97.19 million, a PE ratio of 14.83 and a beta of 1.24.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its holdings in Sensus Healthcare by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after buying an additional 11,525 shares during the last quarter. Ritholtz Wealth Management increased its position in Sensus Healthcare by 65.3% in the 4th quarter. Ritholtz Wealth Management now owns 51,261 shares of the company’s stock valued at $355,000 after acquiring an additional 20,256 shares during the period. XTX Topco Ltd raised its stake in shares of Sensus Healthcare by 76.0% during the third quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after acquiring an additional 13,619 shares during the last quarter. Sigma Planning Corp acquired a new position in shares of Sensus Healthcare during the fourth quarter worth $215,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Sensus Healthcare in the second quarter worth $156,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.